Cefotaxime Resistance in Treatment of Spontaneous Bacterial Peritonitis

Spontaneous bacterial peritonitis (SBP) is a serious complication in cirrhotic patients, and the changes in the microbiological characteristics reported in the last years are impacting the choice of antibiotic used in the treatment. Cefotaxime has been the most extensively studied antibiotic for this infection. It is considered to be one of the first choice antibiotics because of low toxicity and excellent efficacy. Treatment of SBP by intravenous cefotaxime should be administered for a minimum 5 days. Antibiotic-resistant microorganisms have been increasingly reported especially to cefotaxime and its effect on the clinical outcome in treating SBP.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Spontaneous Bacterial Peritonitis

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Nasser institute

Cairo, Shubra, Egypt

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

patients with liver cirrhosis and ascites and clinical findings suspicious of ascitic fluid infection

Exclusion criteria

Patients were excluded if they received antibiotics ten days prior to the hospital admission or there is evidence of secondary bacterial peritonitis, tuberculous peritonitis, malignant ascites or ascites due to other causes e.g. cardiac or renal diseases

Treatment and study plan

Cefotaxime

Drug

Primary outcomes

Organisms detected with their antibiotics sensitivity

Time frame: 8 months

Sponsors and collaborators

Lead sponsor

Dr Ahmed Ali Elbaz

Other Gov

Registry information

Important dates

Study start: 2015
Primary completion: 2015
Study completion: 2015
First posted: Mar 13, 2015
Registry last updated: Jun 4, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed